Anal Cancer Screening Not Warranted in Men Who Have Sex with Men

Share this article:

(ChemotherapyAdvisor) – Anal human papillomavirus (HPV) and precursors of anal cancer are very common in men who have sex with men (MSM); however, a meta-analysis published in the Lancet Oncology online March 23 shows rate of progression to cancer is substantially lower than that for cervical precancerous lesions in women.

“Our findings mean that cervical cancer screening strategies cannot be simply extrapolated to anal cancer screening as current proposals suggest,” said Andrew Grulich, MBBS, MSc, PhD, University of New South Wales, Australia.

A systematic review and meta-analysis of 53 studies found that most men had anal HPV infection and high-grade anal intraepithelial neoplasia (AIN) was present in 20%–30%. Prevalence of infection with high-risk HPV types was substantially higher in HIV-positive men than in HIV negative men (73.5% vs. 37.2%), and precancerous abnormalities were also more common.

An estimated 10% of HIV-positive men develop high-grade AIN annually compared with about 3% of HIV-negative men. “These incidence rates seem to be higher than would be consistent with our estimate of the prevalence of high-grade AIN (29% in HIV-positive MSM and 21% in HIV-negative MSM), unless many of these high-grade lesions regress,” the authors noted.

In this study, the progression rate from high-grade AIN to anal cancer was approximately 1 in 600 per year in HIV-positive men and 1 in 4,000 per year in HIV-negative men. High-grade cervical cancer precursors have a much higher rate of progression to cervical cancer, about 1 in 80 annually.

“The identification of biomarkers to establish which men with high-grade AIN are at highest risk for progression to anal cancer, and which are likely to regress, should be a research priority,” they noted. “Large, good-quality prospective studies are needed to inform the development of anal cancer screening guidelines for MSM.”

Abstract

Podcast

Share this article:

Related Resources

You must be a registered member of Chemotherapy Advisor to post a comment.

Sign Up for Free e-newsletters

Enter Our April Contest

Start the contest today

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs

More in Gastrointestinal Cancers

Updated Results Announced for ThermoDox Use for HCC

Updated Results Announced for ThermoDox Use for HCC

Celsion announced updated results from its HEAT Study post-hoc analysis which examined the use of ThermoDox, a heat-activated liposomal encapsulation of doxorubicin, in combination with radiofrequency ablation (RFA) for the ...

Combined Tobacco, Alcohol Use Spikes Esophageal Cancer Risk

Combined Tobacco, Alcohol Use Spikes Esophageal Cancer Risk

Rates of esophageal squamous cell carcinoma (ESCC) nearly double for those who use tobacco and consume alcohol, compared to individuals who only smoke or drink.

FDA Approves Cyramza for Gastric Cancer

FDA Approves Cyramza for Gastric Cancer

Eli Lilly and Company announced that the FDA has approved Cyramza (ramucirumab) 10mg/mL injection, for the treatment of patients with advanced or metastatic, gastric cancer or gastro-esophageal junction (GEJ) adenocarcinoma, ...